Adamis Pharmaceuticals Corporation
http://www.adamispharmaceuticals.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Adamis Pharmaceuticals Corporation
Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
Pipeline, Commercial Needs Drive Active China Licensing Scene In July
July was an active month for deals between Chinese biopharma firms, as some looked to build their pipelines and others for partners to help commercialize products moving to market. Two ADCs, a GLP-1R/GIPR fusion protein and an IL-4Rα antibody were among the assets changing hands.
Bristol Gets Tumor-Agnostic Second Approval For Augtyro
Already approved for lung cancer, BMS’s ROS1/NTKK inhibitor gets US FDA accelerated approval for solid tumors that are NTRK-fusion positive.
Takeda Goes In On Molecular Glue Degraders With Degron Deal
The company will pay $1.2bn in upfront and milestone fees to access Degron’s GlueXplorer platform across multiple therapeutic areas.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Biosyn Inc.
- Cellegy Holdings Inc
- US Compounding, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice